MIP Technologies and Supelco Launch Selective SPE Product for Extraction of Amphetamine and Related Drugs

MIP Technologies AB and Supelco, a division of Sigma-Aldrich Corporation has announced the launch of a new SupelMIP™ product for the selective extraction of amphetamine and related drugs.

A SPE product has been developed for trace level determinations in forensic, toxicological and pharmaceutical testing. The SPE phase has been evaluated for amphetamine, methamphetamine, phentermine, MDA, MDMA and MDEA. Recoveries are high and the extracts show minimized ion suppression in urine and oral fluids.

The product is currently being tested at the hospital laboratory in Ängelholm, Sweden. This laboratory is accredited for drug screening in workplaces and schools as well as being a confirmative testing reference site for the southern part of Sweden.

"We are very excited to test this new class-selective SPE phase," said Carl Magnusson, Head of the department of Clinical Chemistry, Ängelholm Hospital.

"This new SPE phase provides added value to the customers by being efficiently class selective and allowing for lower limits of quantitation for the confirmation of this common drug of abuse," said An Trinh, Product Manager, Supelco.